CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleLevered free cash flow is $121.83M, above the global median of $18.73M
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
682.44MUSDvs all stocks (USD)
Trailing P/E
5.23xRevenue (TTM)
389.32MUSDvs all stocks (USD)
Profit Margin
33.36%Beta
0.2100xvs all stocks
52-Week Change
190.84%vs all stocks
Market Capitalization
682.44MUSDvs all stocks (USD)
Enterprise Value
1.00BUSDvs all stocks (USD)
Trailing P/E
5.23xForward P/E
2.75xPEG Ratio
0.0490xPrice to Sales (TTM)
1.75xEnterprise to Revenue
2.57xEnterprise to EBITDA
4.20xProfit Margin
33.36%Operating Margin
70.16%Return on Assets (TTM)
47.02%Revenue (TTM)
389.32MUSDvs all stocks (USD)
Revenue per Share (TTM)
2.39USDUpdated Sep 27, 2026Quarterly Revenue Growth
32.60%Gross Profit (TTM)
300.62MUSDvs all stocks (USD)
EBITDA (TTM)
243.61MUSDvs all stocks (USD)
Net Income (TTM)
129.87MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
117.30%Operating Cash Flow (TTM)
185.56MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
121.83MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 27, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%Revenue
296.15MUSDFY2025 · Dec 31, 2025Operating Income
118.76MUSDvs all stocks (USD)
Pre-tax Income
70.03MUSDFY2025 · Dec 31, 2025Income Tax Expense
46.01MUSDFY2025 · Dec 31, 2025Net Income
24.02MUSDFY2025 · Dec 31, 2025EBIT
102.77MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
124.91MUSDFY2025 · Dec 31, 2025Research & Development
95.14MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
82.26MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
4.08MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
32.75MUSDFY2025 · Dec 31, 2025EPS (Basic)
0.1500USDFY2025 · Dec 31, 2025EPS (Diluted)
0.1500USDFY2025 · Dec 31, 2025Basic Shares Outstanding
161.84MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
161.84MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
24.02MUSDFY2025 · Dec 31, 2025Operating Cash Flow
130.69MUSDFY2025 · Dec 31, 2025Free Cash Flow
130.66MUSDDerived from operating cash flow minus capital expenditure. This filing charges 1.88M of depreciation against 34K of capital expenditure, and its own free-cash-flow line reads 127.01M.FY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
215.46MUSDFY2025 · Dec 31, 2025Income Tax Paid
3.54MUSDFY2025 · Dec 31, 2025Interest Paid
30.33MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
24.02MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
1.88MUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
40.80MUSDFY2025 · Dec 31, 2025Stock-based Compensation
17.25MUSDFY2025 · Dec 31, 2025Other Non-cash Items
1.67MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
35.15MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
6.20MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
3.73MUSDFY2025 · Dec 31, 2025Capital Expenditures
-34.00KUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-34.00KUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
0.00USDFY2025 · Dec 31, 2025Long-term Debt Payments
0.00USDFY2025 · Dec 31, 2025Net Financing Cash Flow
0.00USDFY2025 · Dec 31, 2025Shares Outstanding
165.24MSharesUpdated Sep 27, 2026Float Shares
136.76MSharesUpdated Sep 27, 2026Shares Short
18.73MSharesUpdated Sep 27, 2026Short Ratio
12.76daysvs all stocks
Short % of Shares Outstanding
12.38%vs all stocks
% Held by Insiders
3.24%vs all stocks
% Held by Institutions
98.95%vs all stocks
Total Cash (MRQ)
79.13MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
0.4790USDUpdated Sep 27, 2026Total Debt (MRQ)
396.87MUSDvs all stocks (USD)
Current Ratio (MRQ)
6.06xBook Value per Share (MRQ)
-0.9790USDUpdated Sep 27, 2026Total Assets
396.90MUSDvs all stocks (USD)
Total Current Assets
274.18MUSDFY2025 · Dec 31, 2025Total Liabilities
658.74MUSDFY2025 · Dec 31, 2025Total Non-current Assets
122.72MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
416.52MUSDFY2025 · Dec 31, 2025Total Current Liabilities
242.22MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
215.46MUSDFY2025 · Dec 31, 2025Accounts Receivable
46.74MUSDFY2025 · Dec 31, 2025Accounts Payable
2.90MUSDFY2025 · Dec 31, 2025Short-term Debt
202.93MUSDFY2025 · Dec 31, 2025Deferred Revenue
1.11MUSDFY2025 · Dec 31, 2025Other Current Liabilities
9.41MUSDFY2025 · Dec 31, 2025Long-term Debt
394.87MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
21.65MUSDFY2025 · Dec 31, 2025Common Stock (Book)
163.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-1.67BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
-261.83MUSDvs all stocks (USD)
52-Week Low
1.29USDUpdated Sep 27, 202652-Week High
5.78USDUpdated Sep 27, 202652-Week Change
190.84%vs all stocks
Beta
0.2100xvs all stocks
50-Day MA
4.15USDUpdated Sep 27, 2026200-Day MA
3.99USDUpdated Sep 27, 2026Avg 10-Day Volume
2.54MSharesUpdated Sep 27, 2026Avg 30-Day Volume
1.87MSharesUpdated Sep 27, 2026Diluted EPS (TTM)
0.7900USDUpdated Sep 27, 2026Other Income / Expense
-20.06MUSDFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Levered free cash flow is $121.83M, above the global median of $18.73MNotable
Levered free cash flow (USD): 121,834,752Global Median: 18,729,043.027
Companies that share the same coordination system — how they create, deliver, or capture value.
Seers Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
MiMedx Group, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Hunan Hansen Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Sinotherapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Hangzhou AGS Medtech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Gen Ilac ve Saglik Urunleri A.S.
Tier 1ProductionApproval-Gated PipelineRule
Hunan Fangsheng Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Annexon, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Fuan Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zevra Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule